Anzeige
Mehr »
Dienstag, 07.10.2025 - Börsentäglich über 12.000 News
Golden Cross könnte Australiens nächste Goldentdeckung in der Pipeline haben!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QLX7 | ISIN: US4884452065 | Ticker-Symbol: 1GDA
Tradegate
06.10.25 | 21:42
9,100 Euro
0,00 % 0,000
1-Jahres-Chart
ZEVRA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ZEVRA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
9,2009,45011:48
9,2009,45011:23

Aktuelle News zur ZEVRA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
ZEVRA THERAPEUTICS Aktie jetzt für 0€ handeln
MoZevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)42CELEBRATION, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living...
► Artikel lesen
25.09.Zevra Therapeutics rises amid takeover speculation6
17.09.Zevra Therapeutics (ZVRA) Announces Positive New Data Supporting Foundational Role of MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C11
04.09.Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)3
03.09.Zevra Therapeutics: Strategie für seltene Krankheiten auf Cantor-Konferenz vorgestellt23
28.08.Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)2
21.08.Zevra Therapeutics gains amid takeover speculation18
13.08.Zevra Therapeutics: MyPlifa als Wachstumstreiber, doch Herausforderungen bei Alpruva11
13.08.Zevra Reported Its First-Ever Quarterly Profit. Why Shares Of The Top 6% Stock Crashed.13
13.08.Zevra Therapeutics stock price target lowered to $18 at Citizens JMP12
13.08.Zevra signals continued MIPLYFFA momentum with 26% revenue growth and $150M PRV sale strengthening balance sheet11
12.08.ZEVRA THERAPEUTICS, INC. - 10-Q, Quarterly Report2
12.08.Zevra Therapeutics: Zevra Reports Second Quarter 2025 Financial Results and Corporate Update401Q2 2025 net revenue of $25.9 million, driven by product net revenue of $21.8 million Completed sale of PRV for $150.0 million, bolstering the balance sheet as the Company executes on its commercial...
► Artikel lesen
12.08.ZEVRA THERAPEUTICS, INC. - 8-K, Current Report1
11.08.Zevra Therapeutics Q2 2025 Earnings Preview1
11.08.A Look at Zevra Therapeutics' Upcoming Earnings Report3
04.08.Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call5
28.07.Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C162CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living...
► Artikel lesen
18.07.Zevra Therapeutics Announces MIPLYFFA and OLPRUVA Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)2
16.07.Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism235CELEBRATION, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living...
► Artikel lesen
Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2